Form 4: Harvard Apparatus Director David Green Receives Significant Stock Option Grants

Harvard Apparatus Regenerative Technology, Inc. director David Green was granted 33,817 stock options with an exercise price of $1.60, comprising annual equity and compensation-in-lieu grants.

Summary

• David Green, a non-employee director of Harvard Apparatus Regenerative Technology, Inc. (HRGN), acquired a total of 33,817 stock options on June 27, 2025.
• The stock options have an exercise price of $1.60 per share and are set to expire on June 27, 2035.
• One grant of 18,590 stock options represents the annual equity grant for non-employee directors and will vest in four equal installments on September 27, 2025, December 27, 2025, March 27, 2026, and June 27, 2026.
• A second grant of 15,227 stock options was issued in lieu of cash compensation and will vest in four equal installments on the grant date (June 27, 2025), June 30, 2025, September 30, 2025, and December 31, 2025.
• Following these transactions, David Green beneficially owns 33,817 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The filing indicates routine director compensation, which is a positive for aligning interests and retaining talent, but does not contain information that would significantly alter the company's financial outlook or operations.

Positives

• The granting of stock options aligns the interests of the director with shareholders, incentivizing long-term performance and value creation.
• The use of stock options in lieu of cash compensation can help conserve the company's cash reserves.

Negatives

• Potential for minor dilution if and when the stock options are exercised, which is a standard aspect of equity compensation.

Risks

• The value of the stock options is contingent on the company's stock price exceeding the exercise price of $1.60 per share in the future.
• Standard equity compensation risks, including potential future dilution from the exercise of these options.

Future Outlook

The stock option grants, with vesting schedules extending into 2026 and an expiration date in 2035, indicate a long-term incentive structure for the director, aligning future performance with shareholder value.

Industry Context

Equity compensation, particularly stock options, is a common practice across industries, especially in biotechnology and medical device sectors like regenerative technology, to attract and retain talent, align interests, and manage cash flow. The specific exercise price and vesting schedules are typical for director compensation.

Comparison to Industry Standards

• The granting of stock options as part of non-employee director compensation is a standard practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology and medical devices, which Harvard Apparatus Regenerative Technology operates in.
• The vesting schedules, with installments over several quarters or years, are typical for long-term incentive plans, similar to those seen in companies like Organogenesis Holdings Inc. (ORGO) or MiMedx Group, Inc. (MDXG) which also operate in regenerative medicine.
• The exercise price being set at a specific value (e.g., market price on grant date) is also standard, ensuring that the options only have intrinsic value if the stock price appreciates.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for long-term value creation if the stock price appreciates, as director incentives are aligned with shareholder interests. Minor potential for dilution upon exercise of options.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Future vesting dates for the annual equity grant stock options will occur on September 27, 2025, December 27, 2025, March 27, 2026, and June 27, 2026.
• Future vesting dates for the compensation-in-lieu grant will occur on June 30, 2025, September 30, 2025, and December 31, 2025.
• The stock options will expire on June 27, 2035, at which point they must be exercised or will become void.

Key Dates

Recommendation

Keywords

Harvard Apparatus Regenerative Technology, HRGN, Stock Options, Director Compensation, Equity Grant, SEC Form 4, Insider Transaction, Beneficial Ownership, Executive Compensation